- Home
- SYRE
as 10-07-2025 3:29pm EST
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.1B | IPO Year: | 2016 |
| Target Price: | $57.60 | AVG Volume (30 days): | 681.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.91 - $40.26 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Spyre Therapeutics Inc. (SYRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Burrows Scott L | SYRE | Chief Financial Officer | Sep 2 '25 | Sell | $16.26 | 18,428 | $299,639.28 | 97,994 |
Latest Spyre Therapeutics Inc. News
SYRE Breaking Stock News: Dive into SYRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
GlobeNewswire
4 days ago
Spyre Therapeutics Announces Grants of Inducement Awards
Simply Wall St.
23 days ago
Spyre Therapeutics (SYRE) Doses First Patient In Promising SPY072 Phase 2 Trial
GlobeNewswire
23 days ago
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
PR Newswire
4 months ago
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
PR Newswire
4 months ago
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
PR Newswire
4 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
4 months ago
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
Compare SYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.